Henlius Biotech, a subsidiary of China's Fosun Pharma, has entered into a deal with Amberstone Biosciences that could reach $440 million in milestone-based payments. The agreement focuses on T-cell engagers, a class of bispecific antibodies designed to redirect immune cells toward tumor targets.
Amberstone, based in California, brings its T-cell engager platform to the collaboration, while Henlius contributes its development and commercialization capabilities. The deal is structured as a biobucks arrangement, meaning the full value depends on successful progress through pre-clinical and clinical milestones.
This cross-border partnership highlights the growing appetite among Chinese biotechs to license emerging technologies from U.S. startups. It also reflects continued interest in T-cell engagers as a promising cancer immunotherapy approach. The financial terms beyond the headline amount were not detailed in the announcement.